TG Therapeutics, Inc. (FRA:NKB2)

Market Cap	7.02B +56.3%
Revenue (ttm)	699.83M +76.1%
Net Income	386.44M +630.2%
EPS	2.42 +667.5%
Shares Out	n/a
PE Ratio	18.16
Forward PE	29.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,034
Open	48.90
Previous Close	47.00
Day's Range	48.90 - 48.90
52-Week Range	23.22 - 51.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 3, 2026

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 399
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NKB2

Financial Performance

In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 13, 2026

Data Sources Report a data error